Imperial College London
Alternate

ProfessorJaneDavies

Faculty of Medicine, National Heart & Lung Institute

Professor of Paediatric Respirology & Experimental Medicine
 
 
 
//

Contact

 

+44 (0)20 7594 7973j.c.davies

 
 
//

Assistant

 

Mrs Gina Rivellini +44 (0)20 7594 7986

 
//

Location

 

G44Emmanuel Kaye BuildingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Harman:2017:10.1016/j.prrv.2017.03.008,
author = {Harman, K and Dobra, R and Davies, JC},
doi = {10.1016/j.prrv.2017.03.008},
journal = {Paediatric Respiratory Reviews},
pages = {7--9},
title = {Disease-modifying drug therapy in cystic fibrosis},
url = {http://dx.doi.org/10.1016/j.prrv.2017.03.008},
volume = {26},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Whilst substantial progress has been made in the treatment of cystic fibrosis, the disease still carries a significant burden in terms of symptoms, requirement for treatment and early mortality. The last decade has witnessed a new era in the development of small molecule drugs targeting the CFTR protein, which for the first time may provide a truly disease-modifying approach to treatment. This article reviews progress and highlights some of the current and future challenges in CFTR modulator therapies.
AU  - Harman,K
AU  - Dobra,R
AU  - Davies,JC
DO  - 10.1016/j.prrv.2017.03.008
EP  - 9
PY  - 2017///
SN  - 1526-0542
SP  - 7
TI  - Disease-modifying drug therapy in cystic fibrosis
T2  - Paediatric Respiratory Reviews
UR  - http://dx.doi.org/10.1016/j.prrv.2017.03.008
UR  - http://hdl.handle.net/10044/1/51934
VL  - 26
ER  -
Download